Showing results (171-180 of 197) with videos related to

Sort By:
Pageof 20
Biopharmaceutics & Drug Disposition|April 1, 1982
Bioavailability of chlorothiazide from 50, 100, and 250 MG solution dosesM A Osman, R B Patel, D S Irwin, et al.
American Journal of Respiratory Cell and Molecular Biology|November 1, 1994
A protective role for T lymphocytes in asbestos-induced pulmonary inflammation and collagen depositionE Corsini, M I Luster, J Mahler, et al.
The Journal of Infectious Diseases|May 1, 1983
Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic miceA U Gerber, W A Craig, H P Brugger, et al.
Archives of Internal Medicine|June 1, 1985
Streptococcal myositisE M Adams, S Gudmundsson, D E Yocum, et al.
Annals of Internal Medicine|November 1, 1978
Hospital use of antimicrobial drugs. Survey at 19 hospitals and results of antimicrobial control programW A Craig, S J Uman, W R Shaw, et al.
Infection and Immunity|April 1, 1988
Lipid X protects mice against fatal Escherichia coli infectionD T Golenbock, J E Leggett, P Rasmussen, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1981
Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assaysR W Bundtzen, R D Toothaker, O S Nielson, et al.
The Journal of Infectious Diseases|February 1, 1989
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection modelsJ E Leggett, B Fantin, S Ebert, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1983
Pharmacokinetics of piperacillin in subjects with various degrees of renal functionP G Welling, W A Craig, R W Bundtzen, et al.
Infection|January 1, 1980
Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal functionO S Nielsen, R D Toothaker, R W Bundtzen, et al.
Pageof 20